Factory neovessels: Engineered human blood vessels secreting therapeutic proteins as a new drug delivery system

Gene Therapy

Volumn 17, Issue 6, 2010, Pages 745-751

  Compte, M ^a   Alonso Camino, V ^a   Santos Valle, P ^a   Cuesta, A M ^a   Sanchez Martin D ^a   Lopez M R ^a   Vicario, J L ^b   Salas, C ^a   Sanz, L ^a   Alvarez Vallina L ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b Centro de Transfusion   (Spain)

Author keywords

Blood vessels; Cancer; Cell based gene therapy; Human endothelial cells; Human mesenchimal stem cells; Lentivirally transduced ECs

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC CARCINOEMBRYONIC ANTIGEN CD3 DIABODY; CARCINOEMBRYONIC ANTIGEN; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG; CD3 ANTIGEN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER INHIBITION; CELL BASED GENE THERAPY; COLON CARCINOMA; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE HOMING; LYMPHOCYTIC INFILTRATION; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SURVIVAL TIME; T LYMPHOCYTE; TISSUE ENGINEERING; ANIMAL; BLOOD VESSEL; DRUG DELIVERY SYSTEM; DRUG SCREENING; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; LENTIVIRINAE; MESENCHYMAL STEM CELL TRANSPLANTATION; NUDE MOUSE; PROCEDURES; SECRETION (PROCESS); TRANSPLANTATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; BLOOD VESSELS; CARCINOEMBRYONIC ANTIGEN; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICE, NUDE; T-LYMPHOCYTES; TISSUE ENGINEERING; TRANSDUCTION, GENETIC; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; GENETIC THERAPY;

MUS; MUS MUSCULUS;

EID: 77953477857     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.33     Document Type: Article

References (21)

1. Koike N, Fukumura D, Gralla O, Au P, Schechner JS, Jain RK. Tissue engineering: creation of long-lasting blood vessels. Nature 2004; 428: 138-139.
2. Sanz L, Santos-Valle P, Alonso-Camino V, Salas C, Serrano A, Vicario JL et al. Long-term in vivo imaging of human angiogen-esis: critical role of bone marrow-derived mesenchymal stem cells for the generation of durable blood vessels. Microvasc Res 2008; 75: 308-314.
3. Au P, Tam J, Fukumura D, Jain RK. Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood 2008; 111: 4551-4558.
4. Melero-Martin JM, Khan ZA, Picard A, Wu X, Paruchuri S, Bischoff J. In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. Blood 2007; 109: 4761-4768. (Pubitemid 46827769)
5. Melero-Martin JM, De Obaldia ME, Kang SY, Khan ZA, Yuan L, Oettgen P et al. Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res 2008; 103: 128-130.
6. Sanz L, Kristensen P, Blanco B, Faceteau S, Russell SJ, Winter G et al. Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Therapy 2002; 15: 1049-1053.
7. Blanco B, Holliger P, Vile RG, lvarez-Vallina L. Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immunol 2003; 171: 1070-1077.
8. Compte M, Blanco B, Serrano F, Cuesta AM, Sanz L, Bernad A et al. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 2007; 14: 380-388.
9. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126-1136.
10. Compte M, Cuesta AM, Sanchez-Mart́n D, Alonso-Camino V, Vicario JL, Sanz L et al. Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells 2009; 27: 753-760.
11. Holliger P, Manzke O, Span M, Hawkins RE, Fleischmann B, Qinghua L et al. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res 1999; 59: 2909-2916.
12. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Know S et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977.
13. Holliger P, Prospero T, Winter G 'Diabodies:' small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90: 6444-6448.
14. Perisic O, Webb PA, Holliger P, Winter G, Williams RL. Crystal structure of a diabody a bivalent antibody fragment. Structure 1994; 2: 1217-1226.
15. Lazennec G, Jorgensen C. Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells 2008; 26: 1387-1394.
16. Segal DM, Weiner GJ, Weiner LM. Bispecific antibodies in cancer therapy. Curr Opin Immunol 1999; 11: 558-562.
17. Sanz L, Blanco B, Alvarez-Vallina L. Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol 2004; 25: 85-91.
18. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Therapy 2008; 15: 739-752.
19. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 49: 557-563.
20. Roth JC, Curiel DT, Pereboeva L. Cell vehicle targeting strategies. Gene Therapy 2008; 15: 716-729.
21. Eliopoulos N, Francois M, Boivin MN, Martienau D, Galipeau J. Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. Cancer Res 2008; 68: 4810-4818.